Sakura and MEDIPATH Transform Pathology
Sakura and MEDIPATH deploy automated embedding systems in France to enhance cancer diagnostics workflows.


Sakura Finetek Europe and MEDIPATH have joined forces to enhance cancer diagnostics through the deployment of Tissue-Tek AutoTEC® a120 automated embedding systems across multiple pathology centers in France. This collaboration supports MEDIPATH’s commitment to delivering high-quality, timely cancer diagnostics, addressing the growing demand fueled by rising cancer cases. The advanced systems enable automated, standardized embedding, crucial for maintaining diagnostic precision and ensuring efficient workflow.
MEDIPATH processes over 1.5 million cases annually, including 140,000 cancer diagnoses. With Sakura’s expertise, the implementation has optimized workflows and trained technicians, ensuring that the technology delivers its maximum potential. The Tissue-Tek AutoTEC a120’s innovative design preserves sample integrity and enables precise traceability, ensuring reliability in diagnostics while supporting lean management practices in pathology.

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Medicus Pharma reicht Phase‑2b/3‑Protokoll für Teverelix bei der FDA ein

Fresenius Kabi erhält FDA-Warnschreiben nach Fehlern bei der Untersuchung aseptischer Verarbeitung in der Anlage Melrose Park

Discussion